LEIDEN, The Netherlands--(BUSINESS WIRE)--Stem Cell Innovations (SCI), Inc. (OTCBB: SCLL) announced today that the Company has submitted its ACTIVTox® in vitro toxicology suite to ECVAM to seek validation as an alternative to animal testing in the European Union. Toxicity testing in the pharmaceutical and chemical industries is often performed in rodents. The use of ACTIVTox would reduce the need for animals in clinical testing, saving pharmaceutical companies time and money.
